1. Home
  2. MRKR vs THH Comparison

MRKR vs THH Comparison

Compare MRKR & THH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Logo TryHard Holdings Limited Ordinary Shares

THH

TryHard Holdings Limited Ordinary Shares

SELL

Current Price

$0.24

Market Cap

15.6M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
MRKR
THH
Founded
1999
2013
Country
United States
Japan
Employees
N/A
116
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.5M
15.6M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
MRKR
THH
Price
$1.13
$0.24
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
58.6K
90.9K
Earning Date
05-14-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
$305.05
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.19
52 Week High
$2.46
$56.26

Technical Indicators

Market Signals
Indicator
MRKR
THH
Relative Strength Index (RSI) 35.82 33.25
Support Level $0.96 N/A
Resistance Level $1.52 $0.53
Average True Range (ATR) 0.07 0.02
MACD -0.02 -0.00
Stochastic Oscillator 27.91 19.87

Price Performance

Historical Comparison
MRKR
THH

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

Share on Social Networks: